With 6,940 newborns enrolled across five African countries, this was the largest randomized trial of a recombinant BCG vaccine in newborns and the first to report Phase 3 efficacy data…

VPM1002 was evaluated in a large phase 3 study in household contacts of TB patients, assessing safety, immunogenicity, and efficacy across pulmonary and extrapulmonary tuberculosis outcomes.   Here is the…

We are pleased to announce that SLS Europe will be participating in the Union World Conference on Lung Health 2025, the world’s largest and most influential lung health conference. This…

We’re pleased to share that our Managing Director, Dr. Leander Grode, will join the Außenwirtschaftstag 2025 in Berlin as a panelist in Panel 5: “Global erfolgreich – Programme und Instrumente…

Paradigm Shifts in Life Sciences: From Germ Theory to Tomorrow’s Medicines   This year’s SLS Days & TWINCORE Joint Symposium was a special edition merging our annual symposia with TWINCORE.…

It was a pleasure for Serum Life Science Europe GmbH (SLS Europe) to take part in the Niedersächsischer Life Science Tag 2025 in Hannover today, hosted by Niedersachsen.next / BioRegioN.…

SIILTIBCY® is a tuberculosis skin test approved in European Union that detects tuberculosis infection regardless of BCG vaccination status with demonstrated sensitivity and specificity Full marketing authorisation granted by the…

The SLS Europe team, alongside Serum Institute of India Pvt. Ltd., participated in the TBVI Symposium in Les Diablerets, contributing to discussions on the future of TB vaccine development. Our…

SIILTIBCY® is poised to be the first skin test in Europe that accurately detects TB, regardless of BCG vaccination status EMA has given a positive recommendation, with a final decision…